immunoglobulin heavy constant epsilon P1 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored IGHEP1 profile across patient tissues and cancer cell-line models. IGHEP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IGHEP1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, IGHEP1 RNA expression shows 6,065 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight UCEC, THCA, and SKCM as cancer lineages where IGHEP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHEP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHEP1 survival associations across molecular data types. IGHEP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHEP1 RNA expression–survival associations across cancer types. High IGHEP1 expression shows unfavorable associations in UCEC, STAD, ACC, KIRP, LUSC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for IGHEP1 RNA expression.
This table summarizes IGHEP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IGHEP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHEP1 shows lower tumor expression in THCA, COAD, READ and CHOL and higher tumor expression in BRCA and UCEC. The THCA box plot shows higher IGHEP1 RNA expression in normal versus tumor tissue (log2 FC = −0.958, t-test p < 0.001).
This table shows molecular features associated with IGHEP1 in patient tissues and cancer cell lines. In patient samples, IGHEP1 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
